Mainga Hamaluba

A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).Maitland K Obonyo N Hamaluba M Ogoda E Mogaka C Williams TN Newton C Kariuki SM Gibb DM Walker AS Connon R George EC
Wellcome Open Res, (2024). 9:281

Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.Nkumama IN Ogwang R Odera D Musasia F Mwai K Nyamako L Murungi L Tuju J Furle K Rosenkranz M Kimathi R Njuguna P Hamaluba M Kapulu MC Frank R Chmi-Sika study team Osier FHA
Immunity, (2024). 57:1215-1224 e6

Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial.Kiguli S Olupot-Olupot P Hamaluba M Giallongo E Thomas K Alaroker F Opoka RO Tagoola A Oyella S Nalwanga D Nabawanuka E Okiror W Nakuya M Amorut D Muhindo R Ayub Mpoya Mnjalla H Oguda E Williams TN Harrison DA Rowan K Briend A Maitland K
EClinicalMedicine, (2024). 72:102640

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS Dicko A Tinto H Ouedraogo JB Hamaluba M Olotu A Beaumont E Ramos Lopez F Natama HM Weston S Chemba M Compaore YD Issiaka D Salou D Some AM Omenda S Lawrie A Bejon P Rao H Chandramohan D Roberts R Bharati S Stockdale L Gairola S Greenwood BM Ewer KJ Bradley J Kulkarni PS Shaligram U Hill AVS R1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544

Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial.Wamae K Ndwiga L Kharabora O Kimenyi K Osoti V de Laurent Z Wambua J Musyoki J Ngetsa C Kalume P Mwambingu G Hamaluba M van der Pluijm R Dondorp AM Bailey J Juliano J Bejon P Ochola-Oyier L
Wellcome Open Res, (2024). 7:95

Gastroenteritis Rehydration Of children with Severe Acute Malnutrition (GASTROSAM): A Phase II Randomised Controlled trial: Trial Protocol.Olupot-Olupot P Aloroker F Mpoya A Mnjalla H Paasi G Nakuya M Houston K Obonyo N Hamaluba M Evans JA Dewez M Atti S Guindo O Ouattara SM Chara A Sainna HA Amos OO Ogundipe O Sunyoto T Coldiron M Langendorf C Scherrer MF Petrucci R Connon R George EC Gibb DM Maitland K
Wellcome Open Res, (2024). 6:160

Safety and immunogenicity of varied doses of R21/Matrix-M vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang S Datoo MS Otieno E Muiruri C Bellamy D Gathuri E Ngoto O Musembi J Provstgaard-Morys S Stockdale L Aboagye J Woods D Lawrie A Roberts R Keter K Kimani D Ndungu F Kapulu M Njau I Orindi B Ewer KJ Hill AVS Bejon P Hamaluba M
Wellcome Open Res, (2023). 8:450

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M Sang S Orindi B Njau I Karanja H Kamau N Gitonga JN Mugo D Wright D Nyagwange J Kutima B Omuoyo D Mwatasa M Ngetsa C Agoti C Cheruiyot S Nyaguara A Munene M Mturi N Oloo E Ochola-Oyier L Mumba N Mauncho C Namayi R Davies A Tsofa B Nduati EW Aliyan N Kasera K Etyang A Boyd A Hill A Gilbert S Douglas A Pollard A Bejon P Lambe T Warimwe G COVVaccine Trial Group
Wellcome Open Res, (2023). 8:182

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.Downs LO Campbell C Abouyannis M Otiende M Kapulu M Obiero CW Hamaluba M Ngetsa C Andersson MI Githinji G Warimwe G Baisley K Scott JAG Matthews PC Etyang A
J Virus Erad, (2023). 9:100355

[A global core outcome measurement set for snakebite clinical trials].Abouyannis M Esmail H Hamaluba M Ngama M Mwangudzah H Mumba N Yeri BK Mwalukore S Alphan HJ Aggarwal D Alcoba G Cammack N Chippaux JP Coldiron ME Gutierrez JM Habib AG Harrison RA Isbister GK Lavonas EJ Martins D Ribeiro I Watson JA Williams DJ Casewell NR Walker SA Lalloo DG
Med Trop Sante Int, (2023). 3:

A long-term observational study of paediatric snakebite in Kilifi County, south-east Kenya.Abouyannis M Boga M Amadi D Ouma N Nyaguara A Mturi N Berkley JA Adetifa IM Casewell NR Lalloo DG Hamaluba M
PLoS Negl Trop Dis, (2023). 17:e0010987

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.Kimathi D Juan-Giner A Orindi B Grantz KH Bob NS Cheruiyot S Hamaluba M Kamau N Fall G Dia M Mosobo M Moki F Kiogora K Chirro O Thiong'o A Mwendwa J Guantai A Karanja HK Gitonga J Mugo D Ramko K Faye O Sanders EJ Grais RF Bejon P Warimwe GM
Lancet Infect Dis, (2023). 23:974-982

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.Odera DO Tuju J Mwai K Nkumama IN Furle K Chege T Kimathi R Diehl S Musasia FK Rosenkranz M Njuguna P Hamaluba M Kapulu MC Frank R Chmi-Sika Study Team Osier FHA Abdi AI Chi PC de Laurent Z Jao I Kamuya D Kamuyu G Makale J Murungi L Musyoki J Muthui M Mwacharo J Kariuki S Mwanga D Mwongeli J Ndungu F Njue M Nyangweso G Kimani D Ngoi JM Musembi J Ngoto O Otieno E Ooko M Shangala J Wambua J Mohammed KS Omuoyo D Mosobo M Kibinge N Kinyanjui S Bejon P Lowe B Marsh K Marsh V Abebe Y Billingsley PF Sim BKL Hoffman SL James ER Richie TL Audi A Olewe F Oloo J Ongecha J Ongas MO Koskei N Bull PC Hodgson SH Kivisi C Imwong M Murphy SC Ogutu B Tarning J Winterberg M Williams TN
Sci Transl Med, (2023). 15:eabn5993

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.Musasia FK Nkumama IN Frank R Kipkemboi V Schneider M Mwai K Odera DO Rosenkranz M F├╝rle K Kimani D Tuju J Njuguna P Hamaluba M Kapulu MC Wardemann H Abdi AI Abebe Y Bejon P Billingsley PF Bull PC de Laurent Z Hoffman SL James ER Kariuki S Kimathi R Kinyanjui S Kivisi C Makale J Marsh K Mohammed KS Mosobo M Musembi J Musyoki J Muthui M Mwacharo J Ndungu F Ngoi JM Ngoto O Ogutu B Olewe F Omuoyo D OngÔÇÖecha J Otieno E Shangala J Sim BKL Richie TL Wambua J Williams TN Osier Faith HA
Nature Communications, (2022). 13:4098

Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?.van der Pluijm RW Peto TJ Hamaluba M Callery JJ Tripura R White NJ Dondorp AM
Lancet Infect Dis, (2022). 22:765-766

Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt.Mumba N Njuguna P Chi P Marsh V Awuor E Hamaluba M Mauncho C Mwalukore S Masha J Mwangoma M Kalama B Alphan H Wambua J Bejon P Kamuya D Kapulu MC
Front Public Health, (2022). 10:793913

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).Abouyannis M FitzGerald R Ngama M Mwangudzah H Nyambura YK Ngome S Riako D Babu L Lewa F Else L Dily Penchala S Orindi B Mumba N Kalama B Ndungu FM Adetifa I Khoo S Lalloo DG Casewell NR Hamaluba M
Wellcome Open Res, (2022). 7:90

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response.Kapulu MC Kimani D Njuguna P Hamaluba M Otieno E Kimathi R Tuju J Sim BKL Chmi-Sika Study Team
BMC Infect Dis, (2022). 22:86

Children's Oxygen Administration Strategies And Nutrition Trial (COAST-Nutrition): a protocol for a phase II randomised controlled trial.Kiguli S Olopot-Olupot P Alaroker F Engoru C Opoka RO Tagoola A Hamaluba M Mnjalla H Mpoya A Mogaka C Nalwanga D Nabawanuka E Nokes J Nyaigoti C Briend A van Woensel JBM Grieve R Sadique Z Williams TN Thomas K Harrison DA Rowan K Maitland K
Wellcome Open Res, (2021). 6:221

Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya.Orangi S Pinchoff J Mwanga D Abuya T Hamaluba M Warimwe G Austrian K Barasa E
Vaccines (Basel), (2021). 9: